Published in Am J Pathol on September 01, 1998
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol (1999) 4.85
The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci U S A (2005) 4.12
Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci U S A (2006) 3.34
A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell (2008) 2.48
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS One (2010) 1.65
Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol (2003) 1.65
Prostate cancer stem cells. J Pathol (2009) 1.26
Molecular pathology of prostate cancer. J Clin Pathol (2005) 1.22
Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. Am J Pathol (2001) 1.17
Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Am J Pathol (2000) 1.16
Epigenetic gene regulation in stem cells and correlation to cancer. Differentiation (2009) 1.11
The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells. BMC Cell Biol (2002) 1.06
Expression of nodal and nodal receptors in prostate stem cells and prostate cancer cells: autocrine effects on cell proliferation and migration. Prostate (2011) 0.99
The AR dependent cell cycle: mechanisms and cancer relevance. Mol Cell Endocrinol (2011) 0.93
Molecular pathways in prostate cancer. Nephrourol Mon (2013) 0.92
p27 expression in inflammatory bowel disease-associated neoplasia. Further evidence of a unique molecular pathogenesis. Am J Pathol (1999) 0.92
Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells. BMC Biol (2010) 0.92
Conversion of androgen receptor signaling from a growth suppressor in normal prostate epithelial cells to an oncogene in prostate cancer cells involves a gain of function in c-Myc regulation. Int J Biol Sci (2014) 0.91
Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/β-catenin/TCF-4 complex inhibition of c-MYC transcription. Prostate (2014) 0.89
CD133, Trop-2 and alpha2beta1 integrin surface receptors as markers of putative human prostate cancer stem cells. Am J Transl Res (2010) 0.89
Disruption of prostate epithelial differentiation pathways and prostate cancer development. Front Oncol (2013) 0.89
Dysplasia of human prostate CD133(hi) sub-population in NOD-SCIDS is blocked by c-myc anti-sense. Prostate (2009) 0.88
Prostate stem cells in the development of benign prostate hyperplasia and prostate cancer: emerging role and concepts. Biomed Res Int (2013) 0.87
Cells of origin for cancer: an updated view from prostate cancer. Oncogene (2012) 0.87
Prostate Cancer Stem Cells: Research Advances. Int J Mol Sci (2015) 0.84
The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells. Prostate (2014) 0.83
Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate. Am J Pathol (2005) 0.82
Animal models relevant to human prostate carcinogenesis underlining the critical implication of prostatic stem/progenitor cells. Biochim Biophys Acta (2011) 0.81
Immunohistochemical assays in prostatic biopsies processed in Bouin's fixative. J Clin Pathol (2005) 0.80
Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer. Oncotarget (2016) 0.79
Prostate cancer stem cells: the role of androgen and estrogen receptors. Oncotarget (2015) 0.77
Stem cells in genetically-engineered mouse models of prostate cancer. Endocr Relat Cancer (2015) 0.77
Basal Progenitors Contribute to Repair of the Prostate Epithelium Following Induced Luminal Anoikis. Stem Cell Reports (2016) 0.76
The complexities of identifying a cell of origin for human prostate cancer. Asian J Androl (2010) 0.76
Novel In Vivo model for combinatorial fluorescence labeling in mouse prostate. Prostate (2015) 0.76
Cancer cell cycles. Science (1996) 21.29
Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell (1994) 9.48
p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell (1994) 8.90
Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. Development (1990) 8.37
Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med (1997) 5.10
Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res (1992) 4.00
Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science (1996) 3.74
Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell (1994) 3.74
Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med (1997) 3.57
Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A (1994) 3.24
Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res (1995) 3.13
Epithelial stem cells in vivo. J Cell Sci Suppl (1988) 2.99
Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology (1988) 2.38
Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate (1996) 2.21
Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl (1989) 2.12
The zonal anatomy of the prostate. Prostate (1981) 2.09
Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol (1998) 2.07
Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res (1997) 2.05
Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol (1986) 2.01
The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res (1997) 2.00
Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res (1992) 1.98
Normal histology of the prostate. Am J Surg Pathol (1988) 1.83
The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate (1994) 1.79
Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res (1998) 1.70
Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia (1997) 1.64
Early alteration of cell-cycle-regulated gene expression in colorectal neoplasia. Am J Pathol (1996) 1.47
Regional morphology and pathology of the prostate. Am J Clin Pathol (1968) 1.46
Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res (1997) 1.44
p27 expression and gastric carcinoma. Nat Med (1997) 1.40
Differential expression of keratins in the basal and luminal compartments of rat prostatic epithelium during degeneration and regeneration. Prostate (1988) 1.35
Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res (1985) 1.32
Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer (1997) 1.29
Identification of intermediate cell types by keratin expression in the developing human prostate. Prostate (1998) 1.27
Cyclin-dependent kinase inhibitor p27KIP1 in lymphoid tissue: p27KIP1 expression is inversely proportional to the proliferative index. Am J Pathol (1997) 1.26
Immunohistochemical localization of the androgen receptor in rat and human tissues. Endocrinology (1990) 1.23
PSA and PAP as immunohistochemical markers in prostate cancer. Urol Clin North Am (1993) 1.22
Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum Pathol (1994) 1.21
Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res (1997) 1.18
A novel M(r) 32,000 nuclear phosphoprotein is selectively expressed in cells competent for self-renewal. Cancer Res (1993) 1.12
Differential cytokeratin expression in normal, hyperplastic and malignant epithelial cells from human prostate. J Urol (1990) 1.10
Differential expression of cytokeratin mRNA and protein in normal prostate, prostatic intraepithelial neoplasia, and invasive carcinoma. Am J Pathol (1997) 1.09
Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Am J Surg Pathol (1996) 1.08
Cancer prognostics: past, present and p27. Nat Med (1997) 1.06
Cyclins, Cdks, and cyclin kinase inhibitors. Cold Spring Harb Symp Quant Biol (1994) 0.99
Cell proliferation in dysplasia of the prostate: analysis by PCNA immunostaining. Prostate (1995) 0.98
Novel nuclear phosphoprotein pp32 is highly expressed in intermediate- and high-grade prostate cancer. Prostate (1998) 0.97
Widespread distribution of nuclear androgen receptors in the basal cell layer of the normal and hyperplastic human prostate. Virchows Arch A Pathol Anat Histopathol (1993) 0.97
Relation between Bcl-2, cell proliferation, and the androgen receptor status in prostate tissue and precursors of prostate cancer. Prostate (1998) 0.93
Immunohistochemical determination of age related proliferation rates in normal and benign hyperplastic human prostates. Urol Res (1993) 0.89
Androgen receptor expression in prostatic dysplasia (prostatic intraepithelial neoplasia) in the human prostate: an immunohistochemical and in situ hybridization study. Prostate (1996) 0.88
Quantitative determination of prostatic epithelial and stromal hyperplasia by a new technique. Biomorphometrics. Invest Urol (1978) 0.88
Proteins of the rat prostate. III. Effect of testosterone on protein synthesis by the ventral prostate of castrated rats. J Urol (1990) 0.85
Differentiation of rat neonatal ventral prostates grown in a serum-free organ culture system. Prostate (1997) 0.84
The fine structure of the basal cell of human prostate. Lab Invest (1966) 0.83
Androgen receptors in untreated and treated prostatic intraepithelial neoplasia. Eur Urol (1996) 0.79
Pathology of prostatic intraepithelial neoplasia and adenocarcinoma of the prostate: prognostic influences of stage, tumor volume, grade, and margins of resection. Semin Oncol (1994) 0.77
The development of human benign prostatic hyperplasia with age. J Urol (1984) 8.29
Identification of a nuclear protein matrix. Biochem Biophys Res Commun (1974) 5.41
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am (2001) 5.39
Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol (1999) 4.85
The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol (1993) 4.55
Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology (2001) 3.99
A fixed site of DNA replication in eucaryotic cells. Cell (1980) 3.78
Mandatory second opinion surgical pathology at a large referral hospital. Cancer (1999) 3.40
Contributions of the large hydrophobic amino acids to the stability of staphylococcal nuclease. Biochemistry (1990) 3.29
Nuclear protein matrix: association with newly synthesized DNA. Science (1975) 3.27
Nuclear matrix. Isolation and characterization of a framework structure from rat liver nuclei. J Cell Biol (1977) 3.26
Supercoiled loops and eucaryotic DNA replicaton. Cell (1980) 3.24
Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A (1994) 3.24
Sarcomas and related proliferative lesions of specialized prostatic stroma: a clinicopathologic study of 22 cases. Am J Surg Pathol (1998) 3.10
Telepathology diagnosis of prostrate needle biopsies. Hum Pathol (1997) 2.99
Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol (1996) 2.97
Significant human beta-cell turnover is limited to the first three decades of life as determined by in vivo thymidine analog incorporation and radiocarbon dating. J Clin Endocrinol Metab (2010) 2.85
Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. Hum Pathol (2001) 2.68
Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. N Engl J Med (1990) 2.67
Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology (2000) 2.35
Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol (2001) 2.32
Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol (2001) 2.31
Mutant forms of staphylococcal nuclease with altered patterns of guanidine hydrochloride and urea denaturation. Proteins (1986) 2.23
Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci U S A (1990) 2.22
Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made. Am J Surg Pathol (2000) 2.19
Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl (1989) 2.12
Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am (1997) 2.07
The role of the nuclear matrix in the organization and function of DNA. Annu Rev Biophys Biophys Chem (1986) 2.07
Primary renal synovial sarcoma: molecular and morphologic delineation of an entity previously included among embryonal sarcomas of the kidney. Am J Surg Pathol (2000) 2.05
Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res (1996) 2.04
Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology (1995) 2.00
DNA packaging and organization in mammalian spermatozoa: comparison with somatic cells. Biol Reprod (1991) 1.99
Considerations in the isolation of rat liver nuclear matrix, nuclear envelope, and pore complex lamina. Exp Cell Res (1981) 1.99
Increasing incidence of minimal residual cancer in radical prostatectomy specimens. Am J Surg Pathol (1997) 1.97
Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res (1993) 1.96
Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res (1996) 1.87
Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. Am J Surg Pathol (2001) 1.87
Residual structure in large fragments of staphylococcal nuclease: effects of amino acid substitutions. Biochemistry (1989) 1.87
Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol (1994) 1.87
Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol (1997) 1.86
Leiomyosarcoma of the paratesticular region: a clinicopathologic study. Am J Surg Pathol (2001) 1.84
Fungal sinusitis: diagnosis with CT and MR imaging. Radiology (1988) 1.82
Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol (1988) 1.81
Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res (1981) 1.80
Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA (1997) 1.80
One-step evolution of a dimer from a monomeric protein. Nat Struct Biol (1995) 1.75
Contributions of the polar, uncharged amino acids to the stability of staphylococcal nuclease: evidence for mutational effects on the free energy of the denatured state. Biochemistry (1992) 1.75
Low-grade myxoid renal epithelial neoplasms with distal nephron differentiation. Hum Pathol (2001) 1.74
Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res (1995) 1.68
The prostate: an increasing medical problem. Prostate (1990) 1.67
The specific binding of estrogens and androgens to the nuclear matrix of sex hormone responsive tissues. J Biol Chem (1980) 1.66
Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987. J Urol (1990) 1.65
Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol (1991) 1.63
Stem cell features of benign and malignant prostate epithelial cells. J Urol (1998) 1.62
Cystic lesions of the prostate gland. A sonographic--pathologic correlation. J Ultrasound Med (1990) 1.61
Consensus conference on second opinions in diagnostic anatomic pathology. Who, What, and When. Am J Clin Pathol (2000) 1.60
A case showing sclerosing adenosis and an unusual form of basal cell hyperplasia of the prostate. Am J Surg Pathol (1989) 1.59
CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev (1998) 1.59
Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens. Am J Pathol (1991) 1.57
Fourier analysis of cell motility: correlation of motility with metastatic potential. Proc Natl Acad Sci U S A (1989) 1.55
Clinical significance of cell proliferation, microvessel density, and CD44 adhesion molecule expression in renal cell carcinoma. Hum Pathol (2001) 1.55
In situ adenocarcinoma of the bladder. Am J Surg Pathol (2001) 1.54
Prostatic carcinoma with abundant xanthomatous cytoplasm. Foamy gland carcinoma. Am J Surg Pathol (1996) 1.54
The epidemiology of prostate cancer in Jamaica. J Urol (1998) 1.53
The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases. Am J Surg Pathol (1995) 1.53
Future prospects in prostate cancer. Prostate (1999) 1.53
Metastatic prostatic carcinoma to supradiaphragmatic lymph nodes. A clinicopathologic and immunohistochemical study. Am J Surg Pathol (1987) 1.52
Adenosis of the prostate. Histologic features in transurethral resection specimens. Am J Surg Pathol (1994) 1.50
Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol (1990) 1.49
Massive retroperitoneal angiomyolipoma. A lesion that may be confused with well-differentiated liposarcoma. Am J Clin Pathol (1989) 1.47
Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology (1994) 1.45
Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am (1993) 1.45
Methods of radical prostatectomy specimen processing: a novel technique for harvesting fresh prostate cancer tissue and review of processing techniques. Mod Pathol (1993) 1.43
A structural analysis of the role of the nuclear matrix and DNA loops in the organization of the nucleus and chromosome. J Cell Sci Suppl (1984) 1.43
Pathological stage is higher in older men with clinical stage B1 adenocarcinoma of the prostate. J Urol (1989) 1.43
Polymerization of deoxyribonucleotides in relation to androgen-induced prostatic growth. Arch Biochem Biophys (1968) 1.43
Can immunohistochemistry enhance the detection of micrometastases in pelvic lymph nodes from patients with high-grade urothelial carcinoma of the bladder? Am J Clin Pathol (1999) 1.42
Malignant rhabdoid tumor of the uterus. Int J Gynecol Pathol (1989) 1.42
The nuclear protein matrix: isolation, structure, and functions. Adv Enzyme Regul (1976) 1.41
Verumontanum mucosal gland hyperplasia in prostatic needle biopsy specimens. A mimic of low grade prostatic adenocarcinoma. Am J Clin Pathol (1995) 1.39
Ductal adenocarcinoma of the prostate diagnosed on needle biopsy: correlation with clinical and radical prostatectomy findings and progression. Am J Surg Pathol (1999) 1.39
Interaction between tetraethylthiuram disulfide and the sulfhydryl groups of D-amino acid oxidase and of hemoglobin. J Biol Chem (1966) 1.38
Lipomeningioma: report of three cases and review of the literature. Neurosurgery (1989) 1.38
E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology (1999) 1.37
Identification of nuclear matrix proteins in the cancer and normal rat prostate. Cancer Res (1991) 1.35
Stability mutants of staphylococcal nuclease: large compensating enthalpy-entropy changes for the reversible denaturation reaction. Biochemistry (1988) 1.33
Early cell motility changes associated with an increase in metastatic ability in rat prostatic cancer cells transfected with the v-Harvey-ras oncogene. Cancer Res (1988) 1.32
Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. J Urol (1997) 1.32
The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis. J Urol (1988) 1.32
Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cells. Nature (1986) 1.31
Concurrent angiomyolipoma and renal cell neoplasia: a study of 36 cases. Mod Pathol (2001) 1.31
Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer (1997) 1.29
Immunohistochemical localization of nitric oxide synthase in the autonomic innervation of the human penis. J Urol (1993) 1.28
Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci U S A (1992) 1.28
Nuclear-cytoskeletal interactions: evidence for physical connections between the nucleus and cell periphery and their alteration by transformation. J Cell Biochem (1992) 1.27
Renal oncocytosis: a morphologic study of fourteen cases. Am J Surg Pathol (1999) 1.27
Primary malignant melanoma of the urethra: a clinicopathologic analysis of 15 cases. Am J Surg Pathol (2000) 1.27
Correlation of nuclear morphometry with progression of breast cancer. Cancer (1991) 1.26